ABEONA THERAPEUTICS INC. Payments to Acquire Short-term Investments
ABEONA THERAPEUTICS INC. (ABEO) reported Payments to Acquire Short-term Investments of $43.71 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. payments to acquire short-term investments for the quarter ending 2026-06-30 was $24.71M, a 24.44% increase year-over-year.
- ABEONA THERAPEUTICS INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $19.00M, a 60.94% decline year-over-year.
- ABEONA THERAPEUTICS INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $37.78M, a 260.43% increase year-over-year.
- ABEONA THERAPEUTICS INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $100.35M, a 77.18% increase year-over-year.
- ABEONA THERAPEUTICS INC. payments to acquire short-term investments for fiscal 2025 was $206.63M, a 31.61% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. payments to acquire short-term investments for fiscal 2024 was $157.01M, a 204.07% increase from fiscal 2023.
- ABEONA THERAPEUTICS INC. payments to acquire short-term investments for fiscal 2023 was $51.64M, a 33.98% decline from fiscal 2022.
- ABEONA THERAPEUTICS INC. payments to acquire short-term investments for fiscal 2022 was $78.21M, a 287.90% increase from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $43.71M 10-Q · filed 2026-08-13 | $81.49M derived: sum of 3 quarters · filed 2026-08-13 | $181.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $19.00M 10-Q · filed 2026-05-13 | $56.78M derived: sum of 2 quarters · filed 2026-05-13 | $157.13M derived: sum of 3 quarters · filed 2026-05-13 | $176.99M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $37.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $138.13M derived: sum of 2 quarters · filed 2026-03-17 | $157.99M derived: sum of 3 quarters · filed 2026-08-13 | $206.63M 10-K · filed 2026-03-17 |
| 2025-09-30 | $100.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $120.20M derived: sum of 2 quarters · filed 2026-08-13 | $168.85M 10-Q · filed 2025-11-12 | $179.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $19.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $68.50M 10-Q · filed 2026-08-13 | $78.98M derived: sum of 3 quarters · filed 2026-08-13 | $135.62M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $48.65M 10-Q · filed 2026-05-13 | $59.13M derived: sum of 2 quarters · filed 2026-05-13 | $115.77M derived: sum of 3 quarters · filed 2026-05-13 | $176.31M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $10.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $67.12M derived: sum of 2 quarters · filed 2026-03-17 | $127.67M derived: sum of 3 quarters · filed 2026-03-17 | $157.01M 10-K · filed 2026-03-17 |
| 2024-09-30 | $56.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $117.18M derived: sum of 2 quarters · filed 2025-11-12 | $146.53M 10-Q · filed 2025-11-12 | $149.94M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $60.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $89.89M 10-Q · filed 2025-08-14 | $93.31M derived: sum of 3 quarters · filed 2025-08-14 | $127.37M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $29.34M 10-Q · filed 2025-05-15 | $32.76M derived: sum of 2 quarters · filed 2025-05-15 | $66.82M derived: sum of 3 quarters · filed 2025-05-15 | $73.02M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $37.48M derived: sum of 2 quarters · filed 2025-03-20 | $43.67M derived: sum of 3 quarters · filed 2025-03-20 | $51.64M 10-K · filed 2025-03-20 |
| 2023-09-30 | $34.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $40.26M derived: sum of 2 quarters · filed 2024-11-14 | $48.22M 10-Q · filed 2024-11-14 | $82.56M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $6.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $14.16M 10-Q · filed 2024-08-12 | $48.50M derived: sum of 3 quarters · filed 2024-08-12 | $57.93M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $7.96M 10-Q · filed 2024-05-15 | $42.31M derived: sum of 2 quarters · filed 2024-05-15 | $51.73M derived: sum of 3 quarters · filed 2024-05-15 | $78.69M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $34.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $43.77M derived: sum of 2 quarters · filed 2024-03-18 | $70.72M derived: sum of 3 quarters · filed 2024-03-18 | $78.21M 10-K · filed 2024-03-18 |
| 2022-09-30 | $9.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $36.38M derived: sum of 2 quarters · filed 2023-11-13 | $43.87M 10-Q · filed 2023-11-13 | $48.87M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $26.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $34.44M 10-Q · filed 2023-08-08 | $39.44M derived: sum of 3 quarters · filed 2023-08-08 | $39.44M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $7.49M 10-Q · filed 2023-05-11 | $12.49M derived: sum of 2 quarters · filed 2023-05-11 | $12.49M derived: sum of 3 quarters · filed 2023-05-11 | $12.49M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $5.00M derived: sum of 2 quarters · filed 2023-03-29 | $5.00M derived: sum of 3 quarters · filed 2023-03-29 | $20.16M 10-K · filed 2023-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $15.16M 10-Q · filed 2022-11-14 | $46.41M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $15.16M 10-Q · filed 2022-08-11 | $46.41M derived: sum of 3 quarters · filed 2022-08-11 | $62.57M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $15.16M 10-Q · filed 2022-05-13 | $46.41M derived: sum of 2 quarters · filed 2022-05-13 | $62.57M derived: sum of 3 quarters · filed 2022-05-13 | $110.24M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $31.24M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $47.41M derived: sum of 2 quarters · filed 2022-03-31 | $95.08M derived: sum of 3 quarters · filed 2022-03-31 | $170.47M 10-K · filed 2022-03-31 |
| 2020-09-30 | $16.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $63.84M derived: sum of 2 quarters · filed 2021-11-15 | $139.23M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $47.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-28 | $123.06M 10-Q · filed 2021-07-28 | ||
| 2020-03-31 | $75.39M 10-Q · filed 2021-05-17 | |||
| 2018-12-31 | $41.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $66.24M derived: sum of 2 quarters · filed 2020-03-16 | $136.09M 10-K · filed 2020-03-16 | |
| 2018-09-30 | $25.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $94.99M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $69.85M 10-Q · filed 2018-08-09 | |||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |